

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 609 473 A8**

(12)

**CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:

**Corrected version no 1 (W1 A1)**  
**INID code(s) 71**

(51) Int Cl.:

**A61K 31/7008** <sup>(2000.01)</sup> **A61P 31/00** <sup>(2000.01)</sup>  
**A61P 39/00** <sup>(2000.01)</sup>

(48) Corrigendum issued on:

**05.07.2006 Bulletin 2006/27**

(86) International application number:

**PCT/CN2004/000281**

(43) Date of publication:

**28.12.2005 Bulletin 2005/52**

(87) International publication number:

**WO 2004/084916 (07.10.2004 Gazette 2004/41)**

(21) Application number: **04723953.8**

(22) Date of filing: **29.03.2004**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **27.03.2003 CN 03108280**

(71) Applicants:

- **Third Military Medical University Chinese People's Liberation Army P.R. of China Chongqing 400038 (CN)**
- **Bio-Wave Institute of Suzhou Hi-Tech New District Corporation, Ltd Jiangsu 215011 (CN)**
- **Beijing Sino-Hongkong Dafu Science & Technology of Biowave Co., Ltd. Beijing 101200 (CN)**

(72) Inventors:

- **XU, Qiwang, No. 30 Gaotanyan Street Chongqing 400038 (CN)**
- **LIU, Junkang, No. 30 Gaotanyan Street Chongqing 400038 (CN)**
- **YUAN, Zetao, NO. 30 Gaotanyan Street Chongqing 400038 (CN)**

(74) Representative: **Neunert, Peter Andreas**

**Patentanwälte**  
**Westphal, Mussnug & Partner**  
**Am Riettor 5**  
**78048 Villingen-Schwenningen (DE)**

(54) **USE OF ACETYL-D-AMINOGLYCOSAMINE IN TREATMENT OF LOCAL LESIONS AND SYSTEMATIC SYMPTOMS RELATED TO INFECTIONS OF VIRUS OR BACTERIA**

(57) The present invention discloses a use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating local lesions or systematic symptoms caused by infections of virus or bacteria. A parenteral preparation comprising N-acetyl-D-glucosamine or pharmaceutically

acceptable salts thereof as active component is capable of controlling systematic toxic symptoms caused by infections of virus and bacteria and local and systematic lesions caused by endotoxins and exotoxins, and exhibits an excellence rate of 90%.

**EP 1 609 473 A8**